Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Bavarian Nordic initiates Phase I/IIa trial for HPV vaccine

The Phase I/IIa trial will assess the safety, reactogenicity and immunogenicity of the vaccine regimen. Credit: Marco Verch.



  • Bavarian Nordic initiates Phase I/IIa trial for HPV vaccine

Go Top